Item 1. Financial Statements
ITEM
1. FINANCIAL STATEMENTS
NEWHYDROGEN,
INC.
CONDENSED
BALANCE SHEETS
June 30,
December 31,
2026
2025
(Unaudited)
ASSETS
Current assets:
Cash
$ 739,528
$ 1,436,928
Prepaid expenses and other current assets
55,275
6,021
Total current assets
794,803
1,442,949
Property and equipment:
Machinery and equipment
37,225
37,225
Less: accumulated depreciation
( 37,117 )
( 36,986 )
Net property and equipment
108
239
Other assets:
Patents, net of amortization of $ 31,735 and $ 30,224 , respectively
13,601
15,112
Deposit
770
770
Total other assets
14,371
15,882
Total assets
$ 809,282
$ 1,459,070
LIABILITIES, MEZZANINE AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued liabilities
$ 6,448
$ 9,786
Total current liabilities
6,448
9,786
Mezzanine:
Series C Convertible Preferred Stock, 34,461 and 34,853 shares outstanding, respectively
3,446,113
3,485,313
Commitments and contingencies
-
-
Stockholders’ equity (deficit):
Preferred stock, $ 0.0001 par value; 10,000,000 authorized shares
-
-
Common stock, $ 0.0001 par value; 3,000,000,000 authorized shares 814,441,380 and 768,031,041 shares issued and outstanding, respectively
81,444
76,803
Additional paid in capital
179,805,585
178,676,658
Accumulated deficit
( 182,530,308 )
( 180,789,490 )
Total stockholders’ deficit
( 2,643,279 )
( 2,036,029 )
Total liabilities, mezzanine and stockholders’ equity
$ 809,282
$ 1,459,070
The
accompanying notes are an integral part of these condensed financial statements.
1
NEWHYDROGEN,
INC.
CONDENSED
STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenue:
$ -
$ -
$ -
$ -
Operating expenses:
Selling and marketing expenses
109,878
94,092
203,447
200,571
General and administrative expenses
464,318
381,053
861,116
648,506
Research and development
342,874
147,867
674,387
249,385
Depreciation and amortization
821
820
1,642
1,641
Total operating expenses
917,891
623,832
1,740,592
1,100,103
Loss from operations before other income (expense)
( 917,891 )
( 623,832 )
( 1,740,592 )
( 1,100,103 )
Other income (expense):
Interest income
69
128
173
305
Other expenses
-
-
( 399 )
-
Total other income (expense)
69
128
( 226 )
305
Net income (loss)
$ ( 917,822 )
$ ( 623,704 )
$ ( 1,740,818 )
$ ( 1,099,798 )
Basic and diluted earnings (loss) per share
$ ( 0.00 )
$ ( 0.00 )
$ ( 0.00 )
$ ( 0.00 )
Weighted average number of common shares outstanding, basic and diluted
789,922,604
705,126,274
779,037,297
704,861,438
The
accompanying notes are an integral part of these condensed financial statements.
2
NEWHYDROGEN,
INC.
CONDENSED
STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
THREE
AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025
(Unaudited)
Series C
Additional
Preferred Stock
Preferred Stock
Common Stock
Paid in
Accumulated
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Deficit
Total
Balance, December 31, 2025
34,853
$ 3,485,313
-
$ -
768,031,041
$ 76,803
$ 178,676,658
$ ( 180,789,490 )
$ ( 2,036,029 )
Stock compensation cost
-
-
-
-
-
-
140,675
-
140,675
Net loss
-
-
-
-
-
-
-
( 822,996 )
( 822,996 )
Balance, March 31, 2026
34,853
3,485,313
-
-
768,031,041
76,803
178,817,333
( 181,612,486 )
( 2,718,350 )
Issuance of common shares for equity financing at cost
-
-
-
-
46,410,339
4,641
758,394
-
763,035
Stock compensation cost
-
-
-
-
-
-
190,658
-
190,658
Adjustment to mezzanine
( 392 )
( 39,200 )
-
-
-
-
39,200
-
39,200
Net loss
-
-
-
-
-
-
-
( 917,822 )
( 917,822 )
Balance, June 30, 2026
34,461
$ 3,446,113
-
$ -
814,441,380
$ 81,444
$ 179,805,585
$ ( 182,530,308 )
$ ( 2,643,279 )
Balance, December 31, 2024
34,853
$ 3,485,313
-
$ -
704,599,512
$ 70,460
$ 176,508,484
$ ( 177,942,547 )
$ ( 1,363,603 )
Stock compensation cost
-
-
-
-
-
-
55,376
-
55,376
Net loss
-
-
-
-
-
-
-
( 476,094 )
( 476,094 )
Balance, March 31, 2025
34,853
3,485,313
-
-
704,599,512
70,460
176,563,860
( 178,418,641 )
( 1,784,321 )
Issuance of common shares for equity financing at cost
-
-
-
-
803,536
80
29,920
-
30,000
Stock compensation cost
-
-
-
-
-
-
61,151
-
61,151
Net loss
-
-
-
-
-
-
-
( 623,704 )
( 623,704 )
Balance, June 30, 2025
34,853
$ 3,485,313
-
$ -
705,403,048
$ 70,540
$ 176,654,931
$ ( 179,042,345 )
$ ( 2,316,874 )
The accompanying notes are an integral part of these condensed financial statements.
3
NEWHYDROGEN,
INC.
CONDENSED
STATEMENTS OF CASH FLOWS
(Unaudited)
Six Months Ended June 30,
2026
2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)
$ ( 1,740,818 )
$ ( 1,099,798 )
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization
1,642
1,641
Non-cash stock compensation expense
331,333
116,527
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
( 49,254 )
( 26,336 )
Accounts payable and accrued liabilities
( 3,338 )
4,351
Net cash provided by (used in) operating activities
( 1,460,435 )
( 1,003,615 )
CASH FLOWS FROM INVESTING ACTIVITIES:
-
-
CASH FLOWS FROM FINANCING ACTIVITIES:
Common shares issued through an equity financing agreement
763,035
-
Net cash provided by financing activities
763,035
-
Net increase (decrease) in cash
( 697,400 )
( 1,003,615 )
Cash, cash equivalents, and restricted cash - beginning of period
1,436,928
2,104,521
Cash, cash equivalents, and restricted cash - end of period
$ 739,528
$ 1,100,906
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest
$ -
$ -
Income taxes
$ -
$ -
Non-cash investing and financing activities:
Adjustment to mezzanine
$ 39,200
$ -
Equity financing cost
$ -
$ 30,000
The accompanying notes are an integral part of these condensed financial statements.
4
NEWHYDROGEN,
INC.
CONDENSED
NOTES TO FINANCIAL STATEMENTS
AS
OF JUNE 30, 2026
(Unaudited)
1.
ORGANIZATION AND NATURE OF BUSINESS
Organization
NewHydrogen,
Inc. (the “Company”) was incorporated in the state of Nevada on April 24, 2006. The Company, based in Santa Clarita,
California, began operations on April 25, 2006 to develop and market Photovoltaic solar technology products.
Nature
of Business
We
are a developer of clean energy technologies. Our current focus is on developing a green hydrogen production technology that uses water
and heat rather than electricity to produce the world’s cheapest green hydrogen.
Going
Concern
The
accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of June 30, 2026 the Company
has an accumulated deficit of $ 182,530,308 . During the six months ended June 30, 2026 the company had a net loss of $ 1,740,818 and used
$ 1,460,435 of cash from operating activities. These conditions raise substantial doubt about the Company’s ability to continue
as a going concern within one year after the date these financial statements are issued. In order to continue as a going concern, the
Company will need, among other things, additional capital resources. The Company is significantly dependent upon its ability, and will
continue to attempt, to secure additional equity and/or debt financing. There are no assurances that the Company will be successful in
obtaining additional capital.
The
financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts
of and classification of liabilities that might be necessary in the event the Company cannot continue in existence.
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Accounting
The
accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have
been included. Operating results for the three and six months ended June 30, 2026, are not necessarily indicative of the results that
may be expected for the year ending December 31, 2026. For further information refer to the financial statements and footnotes thereto
included in the Company’s Form 10-K for December 31, 2025.
Revenue
Recognition
The
Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement
exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable
is reasonably assured. The Company adopted Accounting Standards Codification (“ASC”) 606, whereby revenue will be recognized
as performance obligations are satisfied, and customers obtain control of goods or services. However, in the event of a loss on a sale
is foreseen, the Company will recognize the loss as it is determined. To date, the Company has not had significant revenues.
5
Cash
and Cash Equivalent
The
Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Concentration
Risk
Cash
includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Company (FDIC) limits. At times
throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of June 30, 2026, the
cash balance in excess of the FDIC limits was $ 489,528 . The Company has not experienced any losses in such accounts and believes it is
not exposed to any significant credit risk in these accounts.
Use
of Estimates
The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these
financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance and the fair
value of stock options. Actual results could differ from those estimates.
Property
and Equipment
Property
and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives:
SCHEDULE OF PROPERTY AND EQUIPMENT
Computer equipment
5 Years
Machinery and equipment
10 Years
Depreciation
expense for the six months ended June 30, 2026 and 2025 was $ 131 and $ 130 , respectively. Depreciation expense for the three months ended
June 30, 2026 and 2025 was $ 66 and $ 65 , respectively.
Intangible
Assets
The
Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering
for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives
continue to be amortized over their useful lives (See Note 6).
SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES
Useful Lives
June 30, 2026
December 31, 2025
Patents
15 years
$ 45,336
$ 45,336
Less accumulated amortization
( 31,735 )
( 30,224 )
Intangible
assets
$ 13,601
$ 15,112
SCHEDULE OF PATENT AMORTIZATION
Remainder of 2026
$ 1,511
2027
3,022
2028
3,022
Thereafter
6,046
Total
$ 13,601
Amortization
expense for the six months ended June 30, 2026 and 2025 was $ 1,511 and $ 1,511 , respectively. Amortization expense for the three months
ended June 30, 2026 and 2025 was $ 755 and $ 755 , respectively.
6
Stock-Based
Compensation
The
Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award.
All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during
which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period).
Determining
the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life
of the stock-based payment and stock price volatility. The Company used Black Scholes to value its stock option awards which incorporated
the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life.
Research
and Development
Research
and development costs are expensed as incurred. Total research and development costs were $ 674,387 and $ 249,385 for the six months ended
June 30, 2026 and 2025, respectively and $ 342,874 and $ 147,867 for the three months ended June 30, 2026 and 2025, respectively.
Advertising
and Marketing
The
Company expenses the cost of advertising and promotional materials when incurred. The advertising and marketing costs were $ 203,447 and
$ 200,571 for the six months ended June 30, 2026 and 2025, respectively and $ 109,878 and $ 94,092 for the three months ended June 30, 2026
and 2025, respectively.
Segment
Reporting
NewHydrogen,
Inc. operates as a single operating segment, focusing on developing clean energy technology.
The
accounting policies of the operating segment are the same as those described in the summary of significant accounting policies. The Company’s
chief operating decision maker (“CODM”) is the Chief Executive Officer and Acting Chief Financial Officer. The CODM assesses
performance for the segment and decides how to allocate resources based on net income (loss) that is reported on the income statement.
The measure of segment assets is reported on the balance sheet as total assets.
As
the Company did not generate revenues in the current period, the CODM assessed Company performance through the achievement of target
identification goals. In addition to the Company’s Statement of Operations, the CODM regularly works to develop budgeted and forecasted
expense information which is used to determine the Company’s liquidity needs and cash allocation.
Net
Earnings (Loss) per Share Calculations
We
follow ASC Subtopic 260-10, Earnings per Share, which specifies the computation, presentation, and disclosure requirements of earnings
per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding.
Diluted income (loss) per share reflects the potential dilution that could occur if stock options or other contracts to issue common
stock were exercised or converted during the period. Dilutive securities having an anti-dilutive effect on diluted earnings per share
are excluded from the calculation.
Due
to the net loss for the three and six months ended June 30, 2026 and 2025, basic and diluted income per share were the same, as all securities
had an anti-dilutive effect. The following table presents potentially dilutive securities that were not included in the computation of
diluted net income per share for the three months ended June 30, 2026 and 2025, as their inclusion would be anti-dilutive.
SCHEDULE OF NET EARNINGS PER SHARE
June 30, 2026
June 30, 2025
Weighted average options to purchase common stock
567,472,527
565,000,000
Weighted average warrants to purchase common stock
20,027,473
228,958,334
7
The
following table presents potentially dilutive securities that were not included in the computation of diluted net income per share for
the six months ended June 30, 2026 and 2025, as their inclusion would be anti-dilutive.
June 30, 2026
June 30, 2025
Weighted average options to purchase common stock
566,243,094
565,000,000
Weighted average warrants to purchase common stock
95,220,995
228,958,334
Fair
Value of Financial Instruments
Fair
Value of Financial Instruments requires disclosure of the fair value information, whether recognized in the balance sheet, where it is
practicable to estimate that value. As of June 30, 2026, the amounts reported for cash, prepaid expenses, accounts payable, and accrued
expenses, approximate the fair value because of their short maturities.
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs
used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:
●
Level
1, defined as observable inputs such as quoted prices for identical instruments in active markets;
●
Level
2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and
●
Level
3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
We
measure certain financial instruments at fair value on a recurring basis. As of June 30, 2026, there were no financial instruments to
report.
Recently
Issued Accounting Pronouncements
In
November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, which requires incremental disclosures about specific expense categories, including
but not limited to, purchases of inventory, employee compensation, depreciation, amortization and selling expenses. The amendments are
effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15,
2027. Early adoption is permitted and the amendments may be applied either prospectively or retrospectively. The Company is currently
evaluating this ASU to determine its impact on the Company’s disclosures. The amendments only impact disclosures and are not expected
to have an impact on the Company’s financial condition and results of operations.
The
Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting
standards that had or will have a material impact on its financial statements.
3.
PREFERRED STOCK
As
of June 30, 2026, the Company had 34,461 shares of Series C Preferred Stock outstanding with a fair value of $ 3,446,113 , and a stated
face value of one hundred dollars ($ 100 ) per share which are convertible into shares of fully paid and non-assessable shares of common
stock of the Company. The holder of the Series C preferred stocks is entitled to receive dividends pari passu with the holders of common
stock. Upon any liquidation, dissolution or winding up of the Company, the holder of each outstanding share of Series C Preferred Stock
is entitled to receive, before any payment is made to holders of common stock, an amount equal to one hundred dollars ($ 100 ) per share,
plus all declared and unpaid dividends thereon, with any remaining assets distributed to holders of common stock. A sale of all or substantially
all of the Company’s assets, a merger or consolidation resulting in a change of control of more than fifty percent (50%) of the
Company’s voting power, or a similar reorganization is deemed a liquidation, dissolutions or winding up for this purpose. The holder
has the right, at any time, at its election, to convert shares of Series C Preferred Stock into common stock at a conversion price of
$ 0.0014 and has no voting rights.
During
the six months ended June 30, 2026, 392 shares of Series C Preferred Stock with a stated value of $ 39,200 were cancelled.
The
Series S Preferred Stock has been classified under mezzanine financing, a hybrid of debt and equity financing that gives a lender the
right to convert debt to an equity interest in a company in case of default, generally, after venture capital companies and other senior
lenders are paid.
8
4.
COMMON STOCK
On
May 2, 2025, the Company entered into a purchase agreement with an investor for the sale of up to $ 3,000,000 worth of common stock (the
“Purchase Agreement”). During the six months ended June 30, 2026, the Company issued 46,410,339 shares of common stock for
$ 769,610 under the Purchase Agreement at prices ranging from $ 0.0155 to $ 0.0194 , pursuant to purchase notices received from the investor.
The finance cost of $ 6,575 was deducted from the gross proceeds, leaving net proceeds of $ 763,035 . During the six months ended June 30,
2025, the Company issued 803,536 shares of common stock for $ 30,000 of commitment fees paid under the Purchase Agreement.
5.
STOCK OPTIONS AND WARRANTS
Stock
Options
The
2022 Incentive Plan authorizes a variety of incentive equity awards consisting of incentive stock options, non-qualified stock options,
restricted stock, restricted stock units, and reserves for issuance up to 500,000,000 shares of the Company’s common stock.
Transactions
involving our options are summarized as follows:
SCHEDULE OF STOCK OPTIONS
Weighted
Average
Weighted
Grant-Date
Number of
Average
Per Share
Options
Exercise Price
Fair Value
Options outstanding at December 31, 2025
565,000,000
$ 0.019
$ 0.005
Granted
2,500,000
$ 0.018
$ 0.018
Canceled/Expired
-
$ -
$ -
Exercised
-
$ -
$ -
Options outstanding at June 30, 2026
567,500,000
$ 0.019
$ 0.005
Details
of our options outstanding as of June 30, 2026, are as follows:
SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OPTIONS OUTSTANDING
Options Exercisable
Weighted Average Exercise Price of
Options Exercisable
Weighted Average Contractual Life
of Options
Exercisable (Years)
Weighted Average Contractual Life
of Options
Outstanding (Years)
507,430,540
0.019
2.35
3.07
On
April 1, 2026, the Company granted 2,500,000 non-qualified stock options to a consultant. The options have an exercise price of $ 0.018 ,
expire on the tenth anniversary of the grant date, and vest 69,444 options per month over a 35-month period from the grant date and the
remaining 69,460 options vest at the end of the 36-month.
Total
stock compensation expense related to the options for the six months ended June 30, 2026, and 2025, was $ 331,333 and $ 116,527 , respectively.
As of June 30, 2026, there was $ 713,294 of unrecognized compensation cost related to the Options, which is expected to be recognized
over a remaining weighted-average vesting period of approximately 0.53 years.
9
The
Company uses the Black Scholes model to value option grants. The Black Scholes model requires the use of these assumptions to determine
the fair value of the stock-based awards. The Company uses management’s best estimates, which include the awards expected term,
the fair value of the common stock, the expected volatility of the price of the common stock, the risk-free interest rate, and the expected
dividend yield of the common stock. The expected term represents the period that the Company’s stock-based awards are expected
to be outstanding. The Company has based its expected term on the simplified method available under U.S. GAAP.
Warrants
Transactions
involving our warrants are summarized as follows:
SCHEDULE OF WARRANTS ACTIVITY
Weighted
Average
Weighted
Grant-Date
Number of
Average
Per Share
Warrants
Exercise Price
Fair Value
Warrants outstanding at December 31, 2025
228,958,334
$ 0.048
$ 0.079
Granted
-
$ -
$ -
Canceled/Expired
( 223,958,334 )
$ 0.049
$ 0.080
Exercised
-
$ -
$ -
Warrants outstanding at June 30, 2026
5,000,000
$ 0.026
$ 0.022
Details
of our warrants outstanding as of June 30, 2026, are as follows:
SCHEDULE OF WARRANTS OUTSTANDING
Warrants Exercisable
Weighted Average
Contractual Life of
Warrants Outstanding
and Exercisable (Years)
5,000,000
0.71
6.
COMMITMENTS AND CONTINGENCIES
Research
Agreement
On
June 28, 2023, the Company entered into a Research Agreement (the “Agreement”) with The Regents of the University of California
(the “University”), on behalf of its Santa Barbara Campus. Pursuant to the Agreement, the University will perform certain
research with respect to Thermochemical Water Splitting for Hydrogen Production from Water. The Agreement provides that the research
will be completed under the direction of Professors Phillip Christopher and Eric McFarland, who will serve as principal Investigators.
The Agreement also sets forth the rights to any data or information developed by the University under the Agreement, as well as the ownership
of any patentable developments or discoveries arising from the Agreement. On November 17, 2025, the Company and the Regents of the University
of California amended the Research Agreement to increase consideration payable to the University to $ 1,690,038 . The effective date of
the Amendment is November 17, 2025 and the term of the Agreement runs through November 30, 2026.
Legal
In
the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising. Such matters are subject
to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these
matters will not have a material adverse effect on the Company’s financial position or results of operations.
As
of June 30, 2026, there were no legal proceedings against the Company.
7.
SUBSEQUENT EVENT
Management
has evaluated subsequent events according to the requirements of ASC TOPIC 855 and has no subsequent events to report except as described
herein.
On
July 8, 2026, the Company issued 5,290,010 shares of common stock pursuant to the Purchase Agreement and received $ 66,983 less clearing
fees of $ 1,191 for a total of $ 65,792 .
10
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.